SECONDARY HYPERPARATHYROIDISM TREATMENT MARKET ANALYSIS
Secondary Hyperparathyroidism Treatment Market: Competitive Analysis
Key players operating in the global secondary hyperparathyroidism treatment market include AbbVie, Inc., Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG, Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc., Deltanoid Pharmaceuticals, and Leo Pharma. Major players are focusing on innovation and new product development, to maintain their position in the market and enhance their share. For instance, in June 2016, OPKO Health introduced Rayaldee (calcifediol) for the treatment of SHPT in adults with stage 3 or 4 of chronic kidney disease.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
